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Introduction: Tacrolimus is the backbone immunosuppressant after solid organ
transplantation. Tacrolimus has a narrow therapeutic window with large intra- and
inter-patient pharmacokinetic variability leading to frequent over- and under-
immunosuppression. While routine therapeutic drug monitoring (TDM) remains the
standard of care, tacrolimus pharmacokinetic variability may be influenced by circadian
rhythms. Our aim was to analyze tacrolimus pharmacokinetic/pharmacodynamic profiles
on circadian rhythms comparing morning and night doses of a twice-daily tacrolimus
formulation.
Methods: This is a post-hoc analysis from a clinical trial to study the area under curve
(AUC) and the area under effect (AUE) profiles of calcineurin inhibition after tacrolimus
administration in twenty-five renal transplant patients. Over a period of 24 h, an intensive
sampling (0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 12.5, 13, 13.5, 14, 15, 20, and 24 h) was carried
out. Whole blood and intracellular tacrolimus concentrations and calcineurin activity were
measured by UHPLC-MS/MS.
Results: Whole blood and intracellular AUC12–24 h and Cmax achieved after tacrolimus
night dose was significantly lower than after morning dose administration (AUC0–12 h) (p <
0.001 for both compartments). AUE0–12 h and AUE12–24 h were not statistically different
after morning and night doses. Total tacrolimus daily exposure (AUC0–24 h), in whole blood
and intracellular compartments, was over-estimated when assessed by doubling the
morning AUC0–12 h data.
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Conclusion: The lower whole blood and intracellular tacrolimus concentrations after night
dose might be influenced by a distinct circadian clock. This significantly lower tacrolimus
exposure after night dose was not translated into a significant reduction of the
pharmacodynamic effect. Our study may provide conceptual bases for better
understanding the TDM of twice-daily tacrolimus formulation.
Keywords: tacrolimus, pharmacodynamic, pharmacokinetics, circadian rhythm, kidney transplantation,
immunosuppression
INTRODUCTION
Tacrolimus (Tac) is the most commonly used immunosuppressor
after solid organ transplantation. After oral Tac administration,
there is a large variability in the rate of absorption and
bioavailability (Staatz and Tett, 2004; Hesselink et al., 2005).
Therapeutic Tac doses are adjusted by monitoring the morning
whole blood trough concentrations (Ctrough), even though some
controversies remain regarding the relationship between Ctrough
and clinical outcomes. The area under concentration-time curve
(AUC) is the most accurate assessment of overall Tac exposure
although it is difficult to implement in clinical daily practice
(Wallemacq et al., 2009). Therefore, routine therapeutic drug
monitoring (TDM) of morning trough concentrations remains as
the standard of care. Data of correlations between Ctrough and
AUC still remains a matter of discussion (Brunet et al., 2019).
Marquet et al. (2018) reported that for twice-daily Tac
formulation, the AUC0–12 h correlated better with C12 than C0.
A poor correlation between Tac dosage and trough levels exists,
thus further research of factors influencing Tac exposure is
strongly recommended (Hesselink et al., 2005; Wallemacq
et al., 2009).
Immunosuppressive drugs have pharmacokinetic (PK)
characteristics that may be influenced by circadian rhythms.
These biological rhythms have been singled out as one of the
causes of intra- and inter-patient variability (Baraldo and
Furlanut, 2006). Several studies have shown the influence of
circadian rhythms in gastric pH, gastric emptying time,
gastrointestinal transit time, cytochrome P450 (CYP) activity
in the liver and renal function, among others (Labrecque and
Bélanger, 1991; Baraldo and Furlanut, 2006). Therefore, circadian
rhythms affect processes of absorption, distribution, metabolism,
and elimination of drugs and ultimately drug exposure and
efficacy (Ohdo, 2007). In this context, differences in the
P-glycoprotein (Pgp, encoded by ABCB1 gene) efflux pump or
in the CYP3A activity, could also affect morning and night Tac
exposures (Hoffmeyer et al., 2000; Baraldo and Furlanut, 2006;
Andreu et al., 2017).
In recent years, several studies have investigated the impact of
circadian rhythms in twice-daily Tac formulation but whether
there is a constant effect of Tac throughout a 24 h period remains
to be concluded. Prado-Velasco et al. (2020) developed the first
PKmodel-based study that supports the relationship between Tac
concentration patterns and the circadian modulation of clearance
and absorption suggesting that Tac intra-patient variability may
be partially explained by circadian rhythms in Tac absorption and
metabolism. However, most studies on twice-daily Tac
formulation analyzed a low number of transplant patients,
employed different Tac determination methodologies and
fasting conditions (Min et al., 1996; Tada et al., 2003; Iwahori
et al., 2005; Park et al., 2007; Satoh et al., 2008; Gustavsen et al.,
2020). Notably, these studies have only evaluated Tac exposure
after the morning dose during the 12 h intervals between the two
daily doses (AUC0–12 h), but differences between the two AUCs
(AUC0–12 h and AUC12–24 h) still need to be studied more
comprehensively (Min et al., 1996; Tada et al., 2003; Iwahori
et al., 2005; Park et al., 2007; Gustavsen et al., 2020). Despite
various reports analyzing the PK differences between day- and
night-time of twice-daily Tac administration, results continue to
be controversial. Furthermore, the effect of circadian rhythms on
intracellular Tac concentrations and, ultimately, on different
calcineurin (CN) activity, has not been fully investigated yet.
The intracellular Tac concentrations on its target site of action
could better reflect Tac exposure and it has been correlated with
clinical outcomes (Capron et al., 2012; Han et al., 2016; Francke
et al., 2020).
Our aim was to investigate whether the influence of circadian
timing system on whole blood following Tac administration of
twice-daily Tac formulations have an impact on intracellular
lymphocyte Tac concentrations and on its pharmacodynamics
(PD) (measured as CN activity inhibition). For this purpose, PK/
PD analysis comparing morning and night Tac AUCs in renal
transplant patients was performed.
METHODS
Study Design
A post-hoc analysis of a prospective, non-randomized clinical trial
was carried out at the Kidney Transplant Unit of Bellvitge
University Hospital (clinicalTrials.gov NCT02961608)
(Fontova et al., 2021). This clinical trial was conducted in
accordance with the Declaration of Helsinki and with the local
ethics committee. The study involved 25 adult recipients who
received a kidney transplant at least 6 months before the
inclusion. Main exclusion criteria for the PK/PD analysis
included patients with severe gastrointestinal disorders or
current infections and patients receiving concomitant drugs
interacting with CYP3A enzymes. Recipients using twice-daily
Tac formulation (Prograf® or Adoport®), with Ctrough between 5
and 10 ng/ml and who signed informed consent were recruited in
this study. No changes of Tac doses at least for 2 weeks before the
PK/PD analysis was mandatory. During the period of 24 h, PK
and PD analysis was conducted by an intensive sampling on the
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following time-points: Pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and
12 following morning Tac dose and 12, 12.5, 13, 13.5, 14, 15, 20,
and 24 h following night Tac dose. The night sampling was
reduced according to the nursery blood draw logistics. Tac
doses were carried out at least 1 h before and 2 h after meals,
every 12 h (at 8:00 am and 08:00 pm) and all patients received the
same Mediterranean diet (breakfast: 9:30 am, lunch: 2:00 pm,
snack: 5:00 pm, dinner: 09:00 pm).
Tacrolimus Measurement and
Pharmacokinetic Data Analysis
The measurement of Tac concentrations in whole blood and
intracellular in peripheral blood mononuclear cells (PBMCs) was
performed using ultra-high-performance liquid chromatography
coupled with tandem mass-spectrometry (UHPLC-MS/MS;
Acquity®-TQD® mass spectrometer) using previously validated
methods by our group (Rigo-Bonnin et al., 2015; van Merendonk
et al., 2020). For intracellular Tac measurement, PBMCs isolation
from whole blood was carried out using Ficoll density gradient.
Thereafter, these PBMCs were lysed with a hypotonic lysis buffer.
All Tac determinations showed concentrations higher than the
limit of quantification either in whole blood or in intracellular
compartments (0.65 and 0.126 ng/ml, respectively).
A non-compartmental PK analysis was carried out to estimate
the most relevant exposure parameters from the individual
concentration-time profiles obtained at steady-state conditions.
Both the whole blood and intracellular concentration-time
profiles were analyzed by using Phoenix-WinNonlin 64 v8.2.
The parameters calculated were: trough concentration values
(Ctrough), denoted as C0, trough concentration before morning
dose; C12, trough concentration before night dose, C24, trough
concentration 12 h after night dose; Cmax, peak concentration
after each Tac dose; Tmax, time to reach Cmax; AUCs, areas under
the concentration-time curves from 0 to 12 h time intervals after
each morning (AUC0–12 h) and night (AUC12–24 h) doses
calculated by the trapezoidal rule; Peak-trough fluctuation
index (PTF) calculated as % PTF  100 × [(Cmax − Ctrough)/
Caverage] where Caverage, was estimated from the ratios AUC0–12/τ
or AUC12–24/τ where τ  12 h; Swing fluctuation index (SFI)
estimated as % SFI  100 × [(Cmax − Ctrough)/Ctrough]. Oral
clearance values (CL/F) were also estimated from the ratios
Dose/AUC.
Calcineurin Activity Measurement and
Pharmacodynamic Analysis
The PD effect of Tac was based on measurements of CN activity
in PBMCs using a method previously validated by our group
(Fontova et al., 2019). Briefly, once PBMCs were isolated and
lysed with the hypotonic buffer used for intracellular Tac
determination, the lysate was incubated for 15 min at 30°C
with an exogenous phosphorylated peptide (RIIp). The
calcium-dependent CN activity dephosphorylates RIIp, and
after solid-phase extraction, dephosphorylated peptide (RII)
and its corresponding internal-standard (RII-IS, isotope-
labelled RII) were determined by UHPLC-MS/MS. All the
extractions showed RII levels higher than the limit of
quantification (0.04 µM).
Distinct PD parameters were calculated from the CN activity-
time profiles at steady-state conditions in PBMCs by using
Phoenix-WinNonlin 64 v8.2. The parameters calculated were:
trough CN activity (Itrough) denoted as, I0, trough CN activity
before morning dose; I12, trough CN activity before night dose;
I24, trough CN activity 12 h after night dose; Imin, minimum
inhibition of CN activity, Inadir, maximum CN inhibition; Tnadir,
time to achieve Inadir; AUEs, areas under the effect-time profiles
from 0 to 12 h time intervals after morning (AUE0–12 h) and night
(AUE12–24 h) doses estimated using the trapezoidal rule. The
AUEs were evaluated from the percentage of inhibition curves
considering either the Imin and Inadir from the 24 h time interval
period as baseline following the Eqs. 1, 2 respectively:
% InhibitionImin  [(Imin − Ix)Imin ] p 100 (1)
% InhibitionInadir  [(Ix − Inadir)Inadir ] p 100 (2)
where Ix was the CN activity at each experimental time.
Genotyping
Genomic DNA was extracted from a peripheral whole-blood
sample using Maxwell RSC® (Promega Corporation, Sydney,
Australia) and was stored at −80°C. Genotyping of the
CYP3A5*3 G > A (rs776746), CYP3A4*22 C > T (rs35599367)
and ABCB1 3435C > T (rs1045642) polymorphisms (SNPs) was
carried out using TaqMan SNP Genotyping Assay (Applied
Biosystems, Foster City, CA, United States) in 384-well plates
that included positive and negative controls. Real-time PCRs were
carried out on the 7900HT Fast Real-time PCR System, Applied
Biosystems (Thermo Fisher Scientific, Waltham, MA,
United States), following standard recommendations. Briefly,
0.5 µl of each probe was mixed with 5 µl iTaq Universal
Probes Supermix, 1 µl genomic DNA (10–20 ng/μl) and 3.5 µl
of DNAse free water. The Real-time conditions were heat to 50°C
for 2°min and 95°C for 10 min in the thermal cycler. This was then
followed by 40 cycles of denaturization at 95°C for 15°s and
annealing/extending at 60°C for 1 min. Samples were genotyped
in CCiT-UB (Centres Científics i Tecnològics) at University of
Barcelona, Campus Bellvitge.
Statistical Analysis
Continuous variables derived from intracellular and whole blood
Tac concentration-time and CN activity-time profiles were
expressed as geometric mean [95% geometric mean interval
confidence]. Tac exposure PK parameters and CN activity PD
parameters estimated after the morning and night doses were
compared by means of a two-sided paired t-test of natural log-
transformed values. In contrast, Wilcoxon tests were performed
for non-parametric variables such as Tmax and Tnadir.
Correlations between the PD and PD parameters were
evaluated by the parametric Pearson’s correlation test. Finally,
demographic and non-continuous variables were described as
median [interquartile range]. Statistical significance was set at
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α  0.05. The statistical packages IBM SPSS v23 and Graphpad
Prism 6.0 were used for the statistical analyses.
RESULTS
Demographic Characteristics
Twenty-five renal transplant recipients from Bellvitge University
Hospital were included in the clinical trial between 2016 and
2018. Patients received an immunosuppressive maintenance
therapy consisting of twice-daily Tac with mycophenolate and
corticosteroids. Three patients with asymmetric morning and
night Tac doses were excluded from this PK/PD analysis. The
demographic, CYP3A and ABCB1 pharmacogenetics and clinical
characteristics of the twenty-two patients are shown in Table 1.
Whole Blood Tacrolimus Pharmacokinetic
Profile
The observed mean Tac concentration-time profiles in whole
blood after morning and night doses are shown in Figure 1A. The
AUC, Caverage and Ctrough values were higher after the morning
dose than the night doses (Table 2). CL/F was 25% higher after
the morning dose with respect to the 12–24 h dosing interval.
After the morning dose, a higher Cmax was achieved than after the
night dose. This was paired with a tendency to shorter Tmax after
the morning dose compared to the night dose, although it did not
reach statistical significance (p  0.182). Also, a higher fluctuation
(PTF and SFI) was observed after morning dose as compared to
the night dose, whereas Ctrough/AUC ratios were lower after the
morning dose (Table 2).
Furthermore, a significant overestimation of the total daily Tac
exposure was observed when the AUC0–24 h was assessed by
doubling the morning AUC0–12 (p  0.002) (Figure 1B). In
most patients, such overestimation was higher than 5% (16/
22) and in some patients greater than 10% (8/22).
As also shown in Table 2, correlation between Ctrough and
Cmax was only observed after the night dose. Strong correlations
were also found between AUC0–12 and C12 and between
AUC12–24 and C24 (r ∼ 0.8), although weaker correlations
between AUC0–12 and C0 or AUC12–24 and C12 were also
found (r ∼ 0.7). Scatter plots of these correlations are
represented in Supplementary Figure S1.
The influence of genotypes on circadian rhythms was assessed.
Frequencies observed in the present study were in accordance
with reported allele frequencies in a Caucasian population and
did not deviate from Hardy–Weinberg distribution. All patients
were of Caucasian ethnicity. A three-way analysis of variance was
applied for log-transformed normalized by dose AUC values with
daytime (morning and night) and SNP (CYPA3A4, CYP3A5 or
ABCB1) as fixed factors and patient as a random factor nested
TABLE 1 | Baseline characteristics of the recipients included in the study (n  22).
Variables N = 22
Sex – Male/Female (%) 15/7 (68/32)
Age (years) 58.19 [48.24–69.08]
Time after transplantation (years) 2.12 [1.00–4.42]
Type of donor - deceased/Living (%) 19/3 (86/14)
Tacrolimus formulation – Prograf®/Adoport® (%) 9/13 (41/59)
Mycophenolate mofetil/sodium (%) 20/2 (91/9)
Other concomitant drugs (%)
Prednisone 19 (76)
Omeprazole 20 (80)
Haematocrit (%) 39.05 [36.80–44.85]
Glomerular filtrate (ml/min) 48.00 [39.75–58.00]
Creatinine (µmol/L) 123.0 [104.0–169.0]
Albumin (g/L) 45.00 [42.75–47.00]
ALT (µkat/L) 0.26 [0.19–0.41]
GGT (µkat/L) 0.42 [0.32–0.73]
Genotype CYP3A5 polymorphism (%)
*1/*3 5 (23)
*3/*3 17 (77)
Genotype CYP3A4 polymorphism (%)
*1/*1 1 (5)
*1/*22 21 (95)
Genotype ABCB1 polymorphism (%)
*T/*T 6 (27)
*C-carriers 16 (73)
Numerical variables are expressed as median [interquartile range], whereas in
parenthesis is represented the percentage for categorical data. CKD-EPI calculation was
used for glomerular filtrate estimation. ALT, alanine aminotransferase; GGT, γ-glutamyl-
transferase.
FIGURE 1 | (A)Whole blood tacrolimus (Tac) concentration-time profiles
along 12 h dose interval after the administration of morning and night dose of
twice-daily Tac. (B). Estimation of the total Tac daily exposure (AUC0–24 h) in
whole blood (red square) by doubling the Tac exposure after themorning
Tac dose (AUC0–12 x2) (red round). Each point joined by a line represented one
patient. Paired t-test between both estimations was applied. **p < 0.01.
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within SNP. Statistically significant differences were always found
between daytimes (p < 0.001), CYP3A5 SNP (p < 0.001), but not
between ABCB1 (p  0.533) and CYP3A4 SNPs (p  0.324).
Therefore, in this line, CYP3A5 1*/3* patients showed lower
AUC/Dose than CYP3A5 3*/3* (p < 0.001) in both morning
and night dose.
TABLE 2 |Comparison of tacrolimus (Tac) pharmacokinetic variables in whole blood and their corresponding correlations after morning Tac dose (0–12 h) and after night Tac
dose (12–24 h) of twice-daily Tac formulation.
Variables Morning dose (0–12 h) Night dose (12–24 h) p
Ctrough (ng/ml) 6.72 [6.00–7.52] 6.03 [5.34–6.82] 0.047a
Cmax (ng/ml) 18.20 [15.58–21.25] 11.12 [9.37–13.20] <0.001a
Tmax (h) 1.52 [1.14–1.98] 1.87 [1.03–2.81] 0.182
b
AUC (ng·h/ml) 115.4 [104.2–127.9] 92.4 [81.5–104.8] <0.001a
Ctrough/AUC 0.058 [0.054–0.062] 0.065 [0.061–0.070] 0.014a
PTF (%) 112.3 [92.3–136.6] 40.6 [22.4–73.4] 0.006a
SFI (%) 161.6 [123.8–211.1] 46.5 [24.4–88.7] 0.003a
Caverage (ng/ml) 9.62 [8.68–10.66] 7.70 [6.79–8.73] <0.001a
CL/F (mg·L/ng·h) 15.74 [12.44–19.91] 19.66 [15.13–25.54] <0.001a
Correlationsc Morning dose (0–12 h) Night dose (12–24 h)
R P R p
C0 vs AUC0–12 h 0.696 <0.001 — —
C12 vs AUC0–12 h 0.810 <0.001 — —
C12 vs AUC12–24 h — — 0.748 <0.001
C24 vs AUC12–24 h — — 0.856 <0.001
C0 vs Cmax 0–12 h 0.341 0.120 — —




Data is represented as geometric mean [95% CI] unless Tmax, that is expressed as median [interquartile range]. Ctrough, trough concentration corresponding at time 12 h for morning dose
and at time 24 h for night dose; Cmax, maximum peak Tac concentration; Tmax, time to reach Cmax; AUC, area under the concentration-time curve from each 12 h dose interval; PTF, peak-
trough fluctuation index defined as [(Cmax − Ctrough)/Caverage]; SFI, swing fluctuation index defined as [(Cmax − Ctrough)/Ctrough]; Caverage, average Tac concentration from each 12 h dose
interval; CL/F, clearance/bioavailability ratio; C0, morning pre-dose concentration at time 0 h; C12, night pre-dose concentration at time 12 h; C24, Tac concentration at time 24 h;
AUC0–12 h, area under the concentration-time curve after the morning dose from 0 to 12 h; AUC12–24 h, area under the concentration-time curve after the night dose from 12 to 24 h.
FIGURE 2 | (A) Intracellular tacrolimus (Tac) concentration-time profiles along 12 h dose interval after the administration of morning and night dose of twice-daily
Tac. (B). Estimation of the total intracellular Tac daily exposure (AUC0–24 h) (red square) by doubling the Tac exposure after the morning Tac dose (AUC0–12 x2) (red
round). Each point joined by a line represented one patient. Paired t-test between both estimations was applied. **p < 0.001. (C,D) Correlations between all whole blood
Tac concentrations and intracellular Tac concentrations sampling after morning and night dose, respectively. Pearson test of Ln transformed data were performed
for correlation analysis.
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Intracellular Tacrolimus Profile
PK profiles of intracellular Tac measured in PBMCs were
comparable to whole blood PK profiles (Figure 2A). Once
again, Tac exposures given by AUCs, Caverage and Ctrough were
higher in the morning when compared to the night dosing
interval (Table 3). Similarly, to whole blood, after the morning
Tac dose, a higher intracellular Cmax was observed compared to
the night dose. Meanwhile, no statistically significant differences
were found between Tmax values, nevertheless there was a
tendency towards greater values at night with respect to the
day-time dose (Table 3). This was in accordance with a more
fluctuating profile (PTF and SFI values) after the morning dose in
contrast to the night dose. No differences regarding, Ctrough/AUC
ratios were found between both time settings (morning and
night) although numerically higher values were observed after
night dose (p  0.085).
As in whole blood, the estimation of AUC0–24 h by doubling
the morning AUC0–12 h, was also overestimated in the
intracellular compartment, although more patients displayed
differences higher than 10% (13/22) (Figure 2B).
In contrast to whole blood, a significant correlation between
Ctrough and Cmax after morning and night doses was observed in
the intracellular compartment (Table 3). Stronger correlations
between all possible combinations between trough
concentrations and AUC values were observed compared to
whole blood (r ∼ 0.9–0.95). The scatter plots representing
these correlations are showed in Supplementary Figure S2. In
addition, significant positive correlations were obtained between
whole blood Tac concentrations and intracellular Tac
concentrations either following morning dose or night dose
(Figures 2C,D).
Calcineurin Activity Profile
The CN activity-time profiles in PBMCs after morning and night
Tac doses are shown in Figure 3A. Similar to whole blood and
intracellular PK profiles, there were clear differences in CN
activity profiles regarding day and night times. Indeed, more
fluctuation occurred after the morning dose. The morning dose
also showed a statistically significant lower Inadir, indicating
higher CN inhibition, than the night dose (Table 4). Although
a significantly higher Itrough was observed after the night dose with
respect to morning dose, the ratio of Itrough/Inadir was still
significantly higher after the morning dose. Moreover, no
differences in Tnadir were found between both Tac doses
(Table 4). The morning dose showed a comparable AUE Imin
and AUE Inadir to the night dose when compared to AUC in whole
blood or intracellular PK (Table 4).
In contrast to whole and intracellular PK estimation, similar
CN inhibition during a 24 h period (AUE0–24 Imin and AUE0–24
Inadir) was obtained when this was assessed by doubling the
morning AUE0–12 h (p  0.972 and 0.826, respectively)
(Figures 3B,C). Furthermore, concerning PD, high
interpatient variability was observed in this estimation and few
patients displayed differences lower than 10% in AUE0–24 Imin (7/
22) and in AUE0–24 Inadir (11/22).
No correlations between Itrough (I0, I12, I24) and AUEs were
observed either in the morning nor in the night dose. However, in
both Tac doses, a strong correlation was observed between I0 and
Inadir (r > 0.8) (Table 4). Scatter plots of these correlations are
represented in Supplementary Figure S3. In addition, significant
inverse weak correlation was observed between CN activities
determinations and whole blood Tac concentrations both after
morning dose and night dose (Figures 3D,E).
TABLE 3 | Comparison of intracellular tacrolimus (Tac) pharmacokinetic variables and their corresponding correlations after morning Tac dose (0–12 h) and after night Tac
dose (12–24 h) of twice-daily Tac formulation.
Variables Morning dose (0–12 h) Night dose (12–24 h) p
Ctrough (pg/milion cells) 32.13 [25.41–40.62] 28.49 [22.42–36.21] 0.018a
Cmax (pg/million cells) 95.0 [72.0–125.3] 61.9 [47.6–80.5] <0.001a
Tmax (h) 1.64 [1.14–2.11] 1.92 [1.46–2.89] 0.475b
AUC (pg·h/million cells) 601.4 [478.1–756.5] 477.3 [373.7–609.7] <0.001a
Ctrough/AUC 0.053 [0.048–0.059] 0.059 [0.055–0.065] 0.085a
PTF (%) 125.8 [105.6–149.9] 66.1 [51.9–84.2] <0.001a
SFI (%) 223.1 [176.5–297.0] 81.9 [59.6–112.4] <0.001a
Caverage (pg/million cells) 50.12 [39.84–63.04] 39.78 [31.14–50,81] <0.001a
Correlationsc Morning dose (0–12 h) Night dose (12–24 h)
R p R p
C0 vs AUC0–12 h 0.902
c <0.001 — —
C12 vs AUC0–12 h 0.899
c <0.001 — —
C12 vs AUC12–24 h — — 0.934c <0.001
C24 vs AUC12–24 h — — 0.940c <0.001
C0 vs Cmax 0–12 h 0.738
c <0.001 — —




Data is represented as geometric mean [95% CI] unless Tmax, that is expressed as median [interquartile range]. Ctrough, trough concentration corresponding at time 12 h for morning dose
and at time 24 h for night dose; Cmax, maximum peak Tac concentration; Tmax, time to reach Cmax; AUC, area under the concentration-time curve from each 12 h dose interval; PTF, peak-
trough fluctuation index defined as [(Cmax − Ctrough)/Caverage]; SFI, swing fluctuation index defined as [(Cmax − Ctrough)/Ctrough]; Caverage, average Tac concentration from each 12 h dose
interval; C0, morning pre-dose concentration at time 0 h; C12, night pre-dose concentration at time 12 h; C24, Tac concentration at time 24 h; AUC0–12 h, area under the concentration-
time curve after the morning dose from 0 to 12 h; AUC12–24 h, area under the concentration-time curve after the night dose from 12 to 24 h.
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DISCUSSION
To the best of our knowledge, this is the first study that
simultaneously evaluates the 24 h time variation in the
pharmacokinetics at steady-state conditions of intracellular
and whole blood Tac, after twice-daily administration. While
the impact on circadian rhythms on whole blood Tac has
previously been documented (Min et al., 1996; Tada et al.,
FIGURE 3 | (A) Pharmacodynamic calcineurin (CN) activity-time profiles along 12 h dose interval after the administration of morning and night dose of twice-daily
Tac. (B) Estimation of the total daily CN inhibition using Imin as baseline (AUE0–24 h Imin) (red square) by doubling the inhibition after the morning Tac dose (AUE0–12 Imin x2)
(red round) and (C), estimating the inhibition using Inadir as baseline, AUE0–24 h Inadir (red square) and AUE0–12 h Inadir x2 (red round). Each point joined by a line represented
one patient. Paired t-test between both estimations was applied. (D,E) Correlations between all whole blood Tac concentrations and CN activities sampling after
morning and night dose, respectively. Pearson test of Ln transformed data were performed for correlation analysis.
TABLE 4 |Comparison of pharmacodynamic variablesmeasured as calcineurin (CN) activity and their corresponding correlations after morning tacrolimus dose (0–12 h) and
after night Tac dose (12–24 h) of twice-daily tacrolimus formulation.
Variables Morning dose (0–12 h) Night dose (12–24 h) p
Itrough (pmol RII/min·mg prot) 296.0 [277.1–316.3] 285.8 [266.1–307.0] 0.040a
Inadir (pmol RII/min·mg prot) 220.1 [204.3–237.2] 238.7 [221.7–257.0] 0.002a
Tnadir (h) 2.16 [1.25–3.49] 2.76 [1.47–4.26] 0.656b
Itrough/Inadir 1.29 [1.25–1.34] 1.20 [1.15–1.24] 0.002a
AUE Imin (pmol RII·h/min·mg prot) 127.7 [112.3–145.2] 120.1 [99.1–145.6] 0.572a
AUE Inadir (pmol RII·h/min·mg prot) 262.4 [216.2–318.4] 245.9 [190.6–317.3] 0.449a
Correlationsc Morning dose (0–12 h) Night dose (12–24 h)
R p R P
I0 vs AUE0–12 h Imin −0.034 0.881 — —
I12 vs AUE0–12 h Imin 0.115 0.609 — —
I12 vs AUE12–24 h Imin — — −0.001 0.968
I24 vs AUE12–24 h Imin — — −0.255 0.252
I0 vs AUE0–12 h Inadir −0.134 0.552 - -
I12 vs AUE0–12 h Inadir 0.125 0.579 - -
I12 vs AUE12–24 h Inadir — — 0.158 0.491
I24 vs AUE12–24 h Inadir — — 0.252 0.257
I0 vs Inadir 0–12 h 0.899 <0.001




Data is represented as geometric mean [95% CI] unless Tnadir that is expressed as median [interquartile range]. Itrough, trough CN activity at time 12 h for morning dose and at time 24 h for
night dose; Inadir, maximum inhibition of CN activity; Tnadir, time to reach Inadir; AUE Imin, area under the effect-time curve of CN inhibition from each 12 h dose interval using Imin as baseline;
Imin, minimum CN inhibition observed along 24 h interval; AUE Inadir, area under the effect-time curve of CN inhibition from each 12 h dose interval using the Inadir observed along 24 h
interval as baseline; I0, morning pre-dose CN activity at time 0 h; C12, night pre-dose CN activity at time 12 h; C24, CN activity concentration at time 24 h; AUE0–12 h, area under the effect-
time curve after the morning dose from 0 to 12 h; AUE12–24 h, area under the effect-time after the night dose from 12 to 24 h.
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2003; Iwahori et al., 2005; Park et al., 2007; Satoh et al., 2008;
Gustavsen et al., 2020), data regarding intracellular Tac has yet to
be reported. Here, we show the influence of circadian rhythms on
intracellular PK after twice-daily Tac administration and their
corresponding PD profiles in kidney transplant recipients.
Notably, we also describe the differences in PK and PD
profiles between the morning and night administration doses
in a standard immunosuppressive regimen based on a twice-daily
Tac formulation.
Our results show different whole blood PK profiles between
the morning and the night Tac doses. Achieved exposures (AUC)
following the night dose were approximately 25% lower than
those achieved following the morning dose. Fluctuations of whole
blood concentrations were also much lower during the 12–24 h
dose intervals rather than after the morning dose. These results
suggest 24 h variations in both the extent and rate of absorption
due to physiological rhythms. Tac is a highly lipophilic drug with
poor aqueous solubility. This is one of the factors contributing to
its low and variable oral bioavailability, but also cytochrome P450
(CYP3A) mediated metabolism or multidrug-resistance
associated protein-mediated efflux should be considered.
Indeed, a day-dependent variability has been reported for
CYP3A gene expression and mediated metabolism of other
several drugs (Martin et al., 2003; Tomalik-Scharte et al.,
2014). In this context, the lower Tac exposure after night dose
could be due to an enhanced CYP3A enzymatic activity during
night-time compared to day-time. This could lead to higher pre-
systemic loss of Tac with lower fraction reaching the bloodstream
and, in turn, to higher CL/F values at the 12–24 h dose interval
with respect to the morning drug intake (19.66 and 15.74 mg·l/
ng·h, respectively). In our study we found lower doses in patients
who expressed CYP3Ap3/p3 SNP compared with expressors of
CYP3Ap1/p3. However, no differences were observed when AUC/
Dose was compared for each individual SNP between morning
and night dose. The study should be performed with a larger
sample size to describe the impact of genotypes on circadian
rhythms. Preclinical studies in different murine models
(Murakami et al., 2008; Okyar et al., 2019) and in non-
humans primates (Iwasaki et al., 2015) have also shown the
influence of circadian variation on the expression and activity
of the Tac extrusion transporter Pgp, in the intestine due to its
regulation by Clock genes. A higher Pgp activity during the night
period also may have contributed to the differences between
morning and night Tac administrations observed. Tamura et al.
(2003) reported a Tac permeability two times greater in the upper
part of the intestine (jejunum) than in the ileum of rats. By
contrast, Pgp activity was dominant in ileum compared to the
jejunum. Considering Tac twice-daily as an immediate release
formulation, major Tac uptake would be expected in the jejunum.
At this point, circadian changes on CYP3A enzymatic activity
would play a more important key role in the different exposures
observed between morning and night administrations than Pgp
extrusion. Our results are in line with those of Prado-Velasco
et al. (2020) in the pediatric population describing the effect of
circadian rhythms on CL.
We also found significantly lower fluctuation values in whole
blood Tac concentrations following the night dose when
compared to the morning dose (PTF, 40.6 and 112.3%; SFI,
46.5 and 161.6%, respectively). These results suggest a lower
absorption rate during the night-time as it was described in the
model of Prado-Velasco et al. (2020). This was also confirmed by
a trend to larger Tmax values at night with respect to the morning
dose (1.87 and 1.52 h, respectively). Differences between Ctrough/
AUC ratios were also observed. Lower values of this ratio were
observed in the morning compared to the night dose interval, as
should be expected when a faster absorption process takes place
(0.058 and 0.065, morning and night respectively). Differences in
the absorption rate could be explained by distinct fasting
conditions before drug administration or reduced gastric
emptying rate due to physiologically slower enterokinetics in
the evening with respect to the day time. Indeed, food intake,
especially after high-fat meals, diminished Tac levels and also
slowed the absorption process as previously reported by Bekersky
et al. (2001). Interestingly, Gustavsen et al. (2020), recently
described that the daily circadian PK variations were largely
affected by the fasting conditions at the time of drug intake
showing lower Cmax and AUC0–12 in non-fasting conditions after
morning Tac dose. In this context, the different eating habits in
relation to morning and evening doses should be considered as
eating habits could influence Tac exposure. The significantly
higher Cmax, Cmax/Ctrough, and AUC observed following
morning Tac dose compared to night dose were in accordance
with some previous reports (Min et al., 1996; Iwahori et al., 2005;
Park et al., 2007; Gustavsen et al., 2020), although other studies
did not find these PK differences (Tada et al., 2003; Satoh et al.,
2008; Gustavsen et al., 2020). However, in the vast majority of
these studies the morning Tac dose intake was undertaken after
breakfast and not in fasting conditions, which differs to our study
(Tada et al., 2003; Satoh et al., 2008).
To our knowledge, our study is the first showing the role of
circadian rhythms on intracellular Tac PK. In this study, whole
blood and intracellular exposures revealed pharmacokinetic
profiles with a similar pattern. Both intracellular and whole
blood concentrations were determined under steady-state
conditions, and kinetic equilibrium between whole blood and
PBMC (intracellular) compartment should have been achieved.
Certainly, peak concentrations were observed at similar times for
whole blood and intracellular Tac. As in whole blood, the
morning dose resulted in a higher exposure than that of the
night dose (601.4 and 477.3 pg·h/million cells, respectively).
Intracellular peak concentrations were also higher at the
0–12 h interval than the 12–24 h interval (95.0 and 61.9 pg/
million cells, respectively) resulting in higher fluctuation (PTF,
125.8 and 66.1%; SFI, 223.1 and 81.9%, respectively). Results
obtained after the morning Tac dose from the first AUC0–12 h
were in accordance with previous studies (Lemaitre et al., 2015;
Klaasen et al., 2018). The lower Cmax/Ctrough ratio, especially after
the morning dose, achieved intracellularly compared to whole
blood suggests a restricted entrance of Tac molecules inside the
cells. It is known that ABCB1 polymorphisms affect the
intracellular Tac exposure in PBMCs (Capron et al., 2010;
Tron et al., 2020). However, no literature has been published
to describe the role of circadian rhythms and Pgp on intracellular
Tac exposure.
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A specular PD/PK profile (whole blood or intracellular) was
shown in our study after either the morning or night Tac dose.
Thus far, the PD analysis measuring CN activity has only been
studied following the morning dose of twice-daily Tac
formulation, but no data has reported the PD effect after the
night dose. Our data showed that despite a lower Inadir following
the morning Tac dose, this was not translated into higher CN
activity inhibition during the first 12 h, thus showing
comparable AUE0–12 h and AUE12–24 h. This may be
explained by the transient PD profile observed after morning
Tac dose characterized by a rapid return to pre-dose levels once
the Inadir was reached, which differs to the more sustained
inhibition after the Inadir, which was noticed following night
dose. Previous studies also showed this rapid recovery of CN
activity to pre-dose levels after the morning Tac dose (Koefoed-
nielsen and Gesualdo, 2002; Koefoed-Nielsen et al., 2006;
Iwasaki et al., 2018; Fontova et al., 2021). Other studies
investigating lymphocyte activation have shown circadian
rhythms displaying higher proinflammatory cytokine
secretion during night time (Benedict et al., 2007; Fortier
et al., 2011).
Until now, most studies analyzing the PK and the PD
properties of twice-daily Tac formulation described the
morning AUC0–12 h as 50% of the total daily dose. The
introduction of new once-daily Tac formulations was
brought in to assess AUC0–24 h even when it was compared
with twice-daily Tac (Tsuchiya et al., 2013; Tremblay et al.,
2017; Marquet et al., 2018). Despite the differences observed
after night Tac dose in fasting conditions, some reports
doubled the analysis of the first AUC0–12 h to illustrate total
daily dose exposure to compare once-and twice-daily Tac
formulations (Iwasaki et al., 2018). Our results showed that
by doubling the AUC0–12 h after morning Tac dose, the
AUC0–24 h was overestimated either in whole blood or
intracellular. High interpatient variability was observed in
PD, which suggests that this estimation should be avoided.
Therefore, the best approach to evaluate real AUC0–24 h for
twice-daily Tac is to measure both AUCs and not using
extrapolations.
The TDM of Tac is based on measuring the whole blood
morning Ctrough levels (Wallemacq et al., 2009; Brunet et al.,
2019). Even though measuring the morning C0 also showed good
correlation with AUC0–12 h, it does not reflect the differences
observed between morning and night AUC and Cmax.
Intracellular results also reinforced these observations (Tron
et al., 2020). Furthermore, our results showed that the I0, I12,
and I24 did not correlate with their previous or posterior AUEs,
suggesting that only measuring pre-dose CN activity is not
sufficient to predict the total CN inhibition after twice-daily
Tac dose.
In conclusion, our data proves that despite a clear impact of
circadian rhythms on whole blood and intracellular Tac PK,
ultimately this effect has a modest impact on Tac PD evaluated
as the degree of CN inhibition. Our study may provide a
conceptual basis for a better understanding of PD/PK Tac
properties of twice-daily Tac formulation in recipients of renal
transplantation.
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FIGURE S1 | Cortical hemodynamic results. A and B. Correlation between
whole blood pre-dose concentrations (C0 and C12) and their corresponding
maximum peak-concentration (Cmax; Cmax 0-12h and Cmax 12-24h). C and D.
Correlation between whole blood trough concentrations (C0 and C12) and
their corresponding posterior area under the curve (AUC; AUC0-12h and
AUC12-24h). E and F. Correlation between whole blood trough
concentrations (C12 and C24) and their corresponding previous AUC (AUC0-
12h and AUC12-24h). For correlation analysis, Pearson test of Ln transformed
data were used.
FIGURE S2 | Cortical hemodynamic results. A and B. Correlation between
intracellular pre-dose concentrations (C0 and C12) and their corresponding
maximum peak-concentration (Cmax; Cmax 0-12h and Cmax 12-24h). C and D.
Correlation between intracellular trough concentrations (C0 and C12) and their
corresponding posterior area under the curve (AUC; AUC0-12h and AUC12-24h). E
and F. Correlation between intracellular trough concentrations (C12 and C24) and
their corresponding previous AUC (AUC0-12h and AUC12-24h). For correlation
analysis, Pearson test of Ln transformed data were used.
FIGURE S3 | Cortical hemodynamic results. A and B. Correlation between
trough CN activities (I0 and I12) and their corresponding posterior AUE Imin (AUE0-12h
Imin and AUE12-24h Imin). C and D. Correlation between trough CN activities (I12 and
I24) and their corresponding previous AUE Imin (AUE0-12h Imin and AUE12-24h Imin). E
and F. Correlation between trough CN activities (I0 and I12) and their corresponding
posterior AUE Inadir (AUE0-12h Inadir and AUE12-24h Inadir). G and H. Correlation
between trough CN activities (I12 and I24) and their corresponding previous AUE
Inadir (AUE0-12h Inadir and AUE12-24h Inadir). I and J. Correlation between pre-dose CN
activities (I0 and I12) and their corresponding maximum peak-inhibition (Inadir; Inadir 0-
12h and Inadir 12-24h). For correlation analysis, Pearson test of Ln transformed data
were used.
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